Breast sarcoma. Choice of treatment tactics. The forecast factors
Abstract
Breast sarcomas are rare heterogeneous tumors in breast and the optimal treatment for them is still under discussion. Patients and methods. We retrospectively reviewed 51 patients with BS between 1999 and 2017 in N.N. Blochin Russian Cancer Research Center Ministry of Health of the Russian Federation. Results. Five-year recurrence-free survival and OS rate were 37.5% and 56.2%, respectively. With median follow-up of 86.4 months, 43.14% patients (22/51) were found with local recurrence and metastasis. 93.33% of all distant metastases and 80% of all relapses were found in patients with stage III disease and G3 with only surgical treatment. Also, 84.61% of all separated metastases were detected in patients in the group with more malignant tumor subtypes (malignant fibrous histiocytoma, spindle cell sarcoma) with surgical treatment only. Conclusion. The combined approach is necessary in the treatment of high-grade sarcomas, taking into account the morphological and immunohistochemical parameters of the tumor. Disease stage and local recurrence were indicated as unfavorable prognostic factors. Surgery remains crucial treatment for breast sarcomas. Mastectomy is not routinely necessary if clear margin could be achieved by local excision.
About the Authors
S. V. Sopromadze
FSBI «N.N. Blokhin national medical research center of oncology» of the Ministry of Health of Russia; Federal State Budgetary Educational Institution of Higher Education «A.I. Yevdokimov Moscow State University of Medicine and Dentistry» of the Ministry of Healthcare of the Russian Federation
Russian Federation
Russian Federation
V. A. Sobolevskiy
FSBI «N.N. Blokhin national medical research center of oncology» of the Ministry of Health of Russia
Russian Federation
Russian Federation
A. A. Fedenko
P.A. Hertsen Moscow Oncology Research Center - branch of FSBI NMRRC of the Ministry of Health of Russia
Russian Federation
Russian Federation
O. V. Krochina
FSBI «N.N. Blokhin national medical research center of oncology» of the Ministry of Health of Russia
Russian Federation
Russian Federation
O. Ju. Gorbacheva
FSBI «N.N. Blokhin national medical research center of oncology» of the Ministry of Health of Russia
Russian Federation
Russian Federation
A. S. Soloveva
FSBI «N.N. Blokhin national medical research center of oncology» of the Ministry of Health of Russia; Pirogov Russian National Research Medical University (RNRMU)
Russian Federation
Russian Federation
References
1. Yin M et al. Primary female breast sarcoma: clinicopathologi-cal features, treatment and prognosis. Sci Rep. 2016;6:31497. DOI: 10.1038/srep31497.
2. Moore MP, Kinne DW Breast sarcoma. Surg Clin North Am. 1996;76:383-392. DOI: 10.1016/S0039-6109(05)70445-X.
3. Kattan MW, Leung DH, Brennan MF. Postoperative nomogram for 12-year sarcoma-specific death. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2002;20:791-796.
4. Zelek L et al. Prognostic factors in primary breast sarcomas: a series of patients with long-term follow-up. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2003;21:2583-2588. DOI: 10.1200/ JCO.2003.06.080.
5. Li N et al. Breast sarcoma. A case report and review of literature. Int J Surg Case Rep. 2016;24:203-205.
6. Hefny AF et al. Stromal sarcoma of the breast: a case report. Asian J Surg. 2004;27:339-341.
7. McGowan TS et al. An analysis of 78 breast sarcoma patients without distant metastases at presentation. International journal of radiation oncology, biology, physics. 2000;46:383-390.
8. Holm M et al. Primary breast sarcoma: a retrospective study over 35 years from a single institution. Acta Oncol. 2016;55:584-590.
9. Rashmi Chugh M et al. Breast sarcoma: treatment. UpTo-Date, Waltham, 2016. http://www.uptodate.com/contents/ breast-sarcoma-treatment.
10. Hsu C, McCloskey SA, Peddi PF. Management of breast sarcoma. Surg Clin North Am. 2016;96:1047-1058.
11. Harris JR, Lippman ME, Morrow M, Osborne CK, ed. Diseases of the Breast. Ed. 4. Philadelphia: Lippincott Williams & Wilkins. 2010:800-802.
12. Testori A et al. Huge malignant phyllodes breast tumor: a real entity in a new era of early breast cancer. World J Surg Oncol. 2015;13:81.
13. Al-Benna S, Poggemann K, Steinau HU, Steinstraesser L. Diagnosis and management of primary breast sarcoma. Breast Cancer Res Treat. 2010;122(3):619-626. DOI: 10.1007/ s10549-010-0915-y.
14. Voutsadakis IA, Zaman K, Leyvraz S. Breast sarcomas: current and future perspectives. Breast. 2011;20:199-204.
15. Wang F, Jia Y, Tong Z. Comparison of the clinical and prognostic features of primary breast sarcomas and malignant phyllodes tumor. Jpn J Clin Oncol. 2015;45:146-152.
16. Воротников ИК. Листовидные опухоли и саркомы молочных желез: клиника, диагностика, лечение. Маммология. 1999;(1):29-34.
17. Феденко АА. Модификация режимов химиотерапии сарком мягких тканей. Старые препараты и новые возможности. Саркомы костей, мягких тканей и опухоли кожи. 2015;(4):3-20.
18. Феденко АА, Конев АА, Анурова ОА и соавт. Ангиосаркомы. Саркомы костей, мягких тканей и опухоли кожи. 2013;(1):24-41.
19. Сопромадзе СВ. Саркомы молочной железы. Обзор литературы. Саркомы костей, мягких тканей и опухоли кожи. 2018;(1):33-38.
20. Сопромадзе СВ. Результаты лечения сарком молочной железы в ФГБУ «НМИЦ онкологии им. Н.Н. Блохина». Саркомы костей, мягких тканей и опухоли кожи. 2018;(2):43-48.
Review
For citations:
Sopromadze S.V., Sobolevskiy V.A., Fedenko A.A., Krochina O.V., Gorbacheva O.J., Soloveva A.S. Breast sarcoma. Choice of treatment tactics. The forecast factors. Bone and soft tissue sarcomas, tumors of the skin. 2019;11(2):25-33. (In Russ.)
Views:
211
Email this article 
